Shenzhen Salubris Pharmaceuticals Co., Ltd
http://www.salubris.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shenzhen Salubris Pharmaceuticals Co., Ltd
Finance Watch: LSP Dementia Fund Closes With €260m For Neurodegenerative Diseases
EQT Life Sciences completed the final close of its inaugural LSP Dementia Fund, far surpassing an initial $100m fundraising goal. Also, Resilience received a $410m commitment from the Department of Defense to fund biomanufacturing and Viking cashed in on Phase I obesity data with a $250m offering.
Finance Watch: Morningside Launches Adiso With More Than $60m In Early Funding
Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations.
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
'Buy China' In Procurement Schemes - Should You Worry?
A recent trade group report points to a rising and alarming "Buy China" trend in procurement rounds in the country. Although largely in medical device bidding, it may potentially affect the pharma sector, an analysis from the recent “4+7” centralized bidding scheme show.
Company Information
- Industry
- Distributors
- Pharmaceuticals
- Services
- Other Names / Subsidiaries
-
- Salubris Biotherapeutics Inc., Splendris Pharmaceuticals GmbH, Genekey Biotech (Chengdu) Co., Ltd., Genemen Biotech (Suzhou) Co., Ltd., Alain Medical (Beijing) Co., Ltd., Shenzhen Keyidun Biomedical Technology Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice